AMGEN INC. $750,000,000 3.000% SENIOR NOTES DUE 2029 $1,000,000,000 3.350% SENIOR NOTES DUE 2032 $1,000,000,000 4.200% SENIOR NOTES DUE 2052 $1,250,000,000 4.400% SENIOR NOTES DUE 2062 Underwriting AgreementUnderwriting Agreement • February 22nd, 2022 • Amgen Inc • Biological products, (no disgnostic substances) • New York
Contract Type FiledFebruary 22nd, 2022 Company Industry JurisdictionAmgen Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of $750,000,000 principal amount of its 3.000% Senior Notes due 2029 (the “2029 Notes”), $1,000,000,000 principal amount of its 3.350% Senior Notes due 2032 (the “2032 Notes”), $1,000,000,000 principal amount of its 4.200% Senior Notes due
AMGEN INC. $1,250,000,000 1.650% SENIOR NOTES DUE 2028 $1,250,000,000 2.000% SENIOR NOTES DUE 2032 $1,150,000,000 2.800% SENIOR NOTES DUE 2041 $1,350,000,000 3.000% SENIOR NOTES DUE 2052 Underwriting AgreementUnderwriting Agreement • August 9th, 2021 • Amgen Inc • Biological products, (no disgnostic substances) • New York
Contract Type FiledAugust 9th, 2021 Company Industry JurisdictionAmgen Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of $1,250,000,000 principal amount of its 1.650% Senior Notes due 2028 (the “2028 Notes”), $1,250,000,000 principal amount of its 2.000% Senior Notes due 2032 (the “2032 Notes”), $1,150,000,000 principal amount of its 2.800% Senior Notes due 2041 (the “2041 Notes”) and $1,350,000,000 principal amount of its 3.000% Senior Notes due 2052 (the “2052 Notes,” and together with the 2028 Notes, the 2032 Notes and the 2041 Notes, the “Securities”) to be issued pursuant to the provisions of an Indenture dated as
AMGEN INC. $1,000,000,000 2.200% SENIOR NOTES DUE 2027 $1,250,000,000 2.300% SENIOR NOTES DUE 2031 $750,000,000 3.150% SENIOR NOTES DUE 2040 $1,000,000,000 3.375% SENIOR NOTES DUE 2050 Underwriting AgreementUnderwriting Agreement • May 6th, 2020 • Amgen Inc • Biological products, (no disgnostic substances) • New York
Contract Type FiledMay 6th, 2020 Company Industry JurisdictionAmgen Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of $1,000,000,000 additional principal amount of its existing 2.200% Senior Notes due 2027 (the “2027 Reopening Notes”), $1,250,000,000 principal amount of its 2.300% Senior Notes due 2031 (the “2031 Notes”), $750,000,000 additional principal amount of its existing 3.150% Senior Notes due 2040 (the “2040 Reopening Notes”) and $1,000,000,000 additional principal amount of its existing 3.375% Senior Notes due 2050 (the “2050 Reopening Notes,” and together with the 2027 Reopening Notes, the 2031 Notes and the 2040 Reopening Notes, the “Securities”).
AMGEN INC. $750,000,000 1.850% SENIOR NOTES DUE 2021 $750,000,000 2.250% SENIOR NOTES DUE 2023 $1,250,000,000 2.600% SENIOR NOTES DUE 2026 $1,000,000,000 4.400% SENIOR NOTES DUE 2045Underwriting Agreement • August 19th, 2016 • Amgen Inc • Biological products, (no disgnostic substances) • New York
Contract Type FiledAugust 19th, 2016 Company Industry JurisdictionAmgen Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of $750,000,000 principal amount of its 1.850% Senior Notes due 2021 (the “2021 Notes”), $750,000,000 principal amount of its 2.250% Senior Notes due 2023 (the “2023 Notes”), $1,250,000,000 principal amount of its 2.600% Senior Notes due 2026 (the “2026 Notes”) and $1,000,000,000 principal amount of its 4.400% Senior Notes due 2045 (the “2045 Notes”), and together with the 2021 Notes, 2023 Notes and the 2026 Notes, the “Securities”) to be issued pursuant to the provisions of an Indenture dated as of May 22, 2014 (the “Indenture”), between the Company and The Bank of New York Mellon Trust Company, N.A., as Trustee (the “Trustee”). Goldman, Sachs & Co., Citigroup Global Markets Inc., Morgan Stanley & Co. LLC and HSBC Securities (USA) Inc. have agreed to act as representatives of
AMGEN INC. $750,000,000 2.125% SENIOR NOTES DUE 2020 $500,000,000 2.700% SENIOR NOTES DUE 2022 $1,000,000,000 3.125% SENIOR NOTES DUE 2025 $1,250,000,000 4.400% SENIOR NOTES DUE 2045 Underwriting AgreementUnderwriting Agreement • May 1st, 2015 • Amgen Inc • Biological products, (no disgnostic substances) • New York
Contract Type FiledMay 1st, 2015 Company Industry JurisdictionAmgen Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of $750,000,000 principal amount of its 2.125% Senior Notes due 2020 (the “2020 Notes”), $500,000,000 principal amount of its 2.700% Senior Notes due 2022 (the “2022 Notes”), $1,000,000,000 principal amount of its 3.125% Senior Notes due 2025 (the “2025 Notes”) and $1,250,000,000 principal amount of its 4.400% Senior Notes due 2045 (the “2045 Notes”, and together with the 2020 Notes, 2022 Notes and the 2025 Notes, the “Securities”) to be issued pursuant to the provisions of an Indenture dated as of May 22, 2014 (the “Indenture”), between the Company and The Bank of New York Mellon Trust Company, N.A., as Trustee (the “Trustee”). Morgan Stanley & Co. LLC, Credit Suisse Securities (USA) LLC, Goldman, Sachs & Co. and Merrill Lynch, Pierce, Fenner & Smith Incorporated have agreed t
AMGEN INC. $500,000,000 6.15% SENIOR NOTES DUE 2018 $500,000,000 6.90% SENIOR NOTES DUE 2038 Underwriting AgreementUnderwriting Agreement • May 23rd, 2008 • Amgen Inc • Biological products, (no disgnostic substances) • New York
Contract Type FiledMay 23rd, 2008 Company Industry JurisdictionAmgen Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of $500,000,000 principal amount of the 6.15% Senior Notes due 2018 of the Company (the “2018 Notes”) and an aggregate of $500,000,000 principal amount of the 6.90% Senior Notes due 2038 of the Company (the “2038 Notes” and, together with the 2018 Notes, the “Securities”) to be issued pursuant to the provisions of an Indenture, dated as of August 4, 2003 (the “Indenture”), between the Company and the Bank of New York, as successor to JPMorgan Chase Bank, N.A., as Trustee (the “Trustee”).